Showing 109 results
-
Media Release /Montreal, Quebec, December 5, 2023 — Novartis Canada announces that Mark Vineis has been appointed to the role of Country President, effective as of January 1, 2024. Mark brings a wealth of…
-
Story /Novartis making history in blood cancer for decades
-
Media Release /The Biome Summit 2021 will help fuel debate, drive innovation and advance action on cardiovascular disease as a critical public health issue Montreal, Quebec, August 26, 2021 – Novartis…
-
Media Release /The product of over 120 consultations with health care practitioners, the Novartis Pro Portal is a one-stop digital hub developed to provide tailored, real-time support in daily practice. Dorval…
-
Media Release /Kesimpta® (ofatumumab) delivers superior efficacy with a favourable safety profile and can be self-administered at home, addressing a significant unmet need for people living with relapsing…
-
Media Release /Clinical trial will study new technology that tracks eye movement to assist diagnosis and monitor disease progression Dorval, Quebec, October 5, 2021 — Novartis Pharmaceuticals Canada Inc. (…
-
Media Release /This World Sight Day, Fighting Blindness Canada and the Canadian Council of the Blind have partnered with Novartis Canada to launch “All Eyes on You”, a campaign urging Canadians to lend their…
-
Media Release /Public reimbursement is effective October 20th and will apply for children with SMA following the recommendation from the Institut national d'excellence en santé et services sociaux Zolgensma is…
-
Media Release /KISQALI® is currently the only CDK4/6 inhibitor that has demonstrated statistically significant improvement in overall survival (key secondary endpoint) with various endocrine treatment partners…
-
Media Release /In Canada, cardiovascular disease accounted for more than 52,000 deaths annually between 2015 and 20191 Almost 80% of deaths from cardiovascular disease are preventable2. Novartis is joining…
